The review highlights the potential of anthocyanin-rich products to improve endothelial function and reduce senescence, which is exciting for cardiovascular health research. However, given the known challenge of low anthocyanin bioavailability, I wonder how well the in vitro and preclinical findings translate to real-world human physiology. For example, many of the studies referenced use concentrations that are unlikely to be achieved through dietary consumption. Would the authors consider whether these effects are reproducible at physiologically relevant doses? Moreover, how might advancements in delivery systems, like encapsulation or metabolite stabilization, overcome this barrier to clinical application?
